Advocating for Women’s Health Investment
Exploring the Value of Women’s Health Investments
J.P. Morgan is set to host a series of panels focusing on women’s health at this year’s conference, emphasizing the significance of innovation and enhanced awareness surrounding women’s health issues.
SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a frontrunner in advancing women’s health solutions, has announced that Sabrina Martucci Johnson, the President and CEO, will participate in the ARPA-H | Investing in Women’s Health panel at the prestigious 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. This panel is scheduled for Tuesday, January 14th, at 2:15 p.m. PT, followed by two additional discussions: The Future of Women’s Health Care and Flow of Capital to Women’s Health.
“It’s incredibly encouraging to see women’s health gaining such prominent attention as we enter the new year; beginning with our collaboration to ring the Nasdaq closing bell alongside the Advanced Research Projects Agency for Health (ARPA-H) on January 2nd, and now with the Women’s Health Series during the J.P. Morgan conference,” stated Ms. Johnson. “Building on last year’s momentum, we aim to continually elevate the conversation around women’s health and advocate for increased investments. Daré is strategically situated with innovative products undergoing development that have the potential to be highly disruptive therapeutic options for women across various health sectors, including contraception, sexual health, menopause, infectious diseases, fertility, and pelvic pain.”
In addition to the J.P. Morgan conference, Ms. Johnson will also be highlighted at an event hosted by Grant Engine on Wednesday, January 15th, at 1:55 p.m. PT. The session, titled Fueling Innovation with Non-Dilutive Funding, will showcase the approximately $10 million in non-dilutive funding awards Daré secured in 2024 to support the development of a novel non-hormonal contraceptive candidate and an HPV treatment aimed at preventing cervical cancer.
About Daré Bioscience
Daré Bioscience is a dedicated biopharmaceutical firm focused on creating innovative solutions for women’s health. The company is committed to identifying, developing, and introducing a diverse array of differentiated therapies that emphasize women’s wellness, expand treatment possibilities, and enhance outcomes in areas including contraception, sexual health, pelvic pain, fertility, infectious diseases, and menopause.
The first FDA-approved product from Daré’s portfolio is XACIATO™ (clindamycin phosphate) vaginal gel 2%, which is indicated for treating bacterial vaginosis in women aged 12 years and older, under a global licensing agreement with Organon. Daré’s pipeline also features potential first-in-category candidates currently in clinical development, including Ovaprene®, an innovative hormone-free monthly intravaginal contraceptive with U.S. commercial rights licensed to Bayer; Sildenafil Cream, 3.6%, aimed at treating female sexual arousal disorder; and DARE-HRT1, a bio-identical estradiol and progesterone intravaginal ring for menopause management. For more information on Daré’s complete product offerings and commitment to enhancing women’s health, please visit their website.
Recognized as a leader in the industry, Daré’s leadership has been acknowledged in the Medicine Maker’s Power List and Endpoints News’ Women in Biopharma 2022. The CEO has been celebrated for contributions to innovation and advocacy for women’s health, and the company was honored as the top Small Company in the San Diego Business Journal’s 2023 Best Places to Work Awards.
Forward-Looking Statements
Daré advises that statements beyond historical facts in this release are forward-looking and include terms like “believe,” “may,” “will,” “estimate,” and others indicating potential scenarios. These statements encompass expectations regarding investment in women’s health, product candidate development, regulatory approval possibilities, and projected commercial potential. These forward-looking words involve risks and uncertainties that may result in actual outcomes differing significantly from the expectations set forth. Risks include the ability to acquire necessary funding, the unpredictable nature of clinical trials, and the pressure to achieve milestones required for regulatory approvals. For comprehensive risk factors, refer to the SEC filings, including Forms 8-K, 10-K, and 10-Q.
Contacts:
Daré Bioscience Investor Relations
[email protected]
Source: Daré Bioscience, Inc.
